See more : Izotropic Corporation (IZO.CN) Income Statement Analysis – Financial Results
Complete financial analysis of Eisai Co., Ltd. (ESAIY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eisai Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Bellway p.l.c. (BLWYF) Income Statement Analysis – Financial Results
- ZheJiang HuaSheng Technology Co.,Ltd (605180.SS) Income Statement Analysis – Financial Results
- ORION Corp. (271560.KS) Income Statement Analysis – Financial Results
- BP p.l.c. (BP-B.L) Income Statement Analysis – Financial Results
- Inception Growth Acquisition Limited (IGTA) Income Statement Analysis – Financial Results
Eisai Co., Ltd. (ESAIY)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.eisai.co.jp
About Eisai Co., Ltd.
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. It has strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin antibody drug conjugate. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 741.75B | 744.40B | 756.23B | 645.94B | 695.62B | 642.83B | 600.05B | 539.10B | 547.92B | 548.47B | 600.35B | 573.68B | 647.93B | 768.93B | 803.14B | 781.71B | 734.42B | 674.18B | 601.26B | 533.14B | 500.13B | 466.61B | 431.75B | 361.71B | 302.47B |
| Cost of Revenue | 155.33B | 177.84B | 174.83B | 161.31B | 175.69B | 184.49B | 201.25B | 195.91B | 194.46B | 193.60B | 188.16B | 174.11B | 173.35B | 167.78B | 160.73B | 152.41B | 118.94B | 109.37B | 104.51B | 98.61B | 97.18B | 102.47B | 101.57B | 98.60B | 91.68B |
| Gross Profit | 586.42B | 566.57B | 581.40B | 484.63B | 519.93B | 458.34B | 398.80B | 343.19B | 353.46B | 354.87B | 412.20B | 399.57B | 474.57B | 601.15B | 642.41B | 629.29B | 615.48B | 564.81B | 496.75B | 434.53B | 402.95B | 364.15B | 330.18B | 263.11B | 210.79B |
| Gross Profit Ratio | 79.06% | 76.11% | 76.88% | 75.03% | 74.74% | 71.30% | 66.46% | 63.66% | 64.51% | 64.70% | 68.66% | 69.65% | 73.24% | 78.18% | 79.99% | 80.50% | 83.81% | 83.78% | 82.62% | 81.50% | 80.57% | 78.04% | 76.47% | 72.74% | 69.69% |
| Research & Development | 169.02B | 173.00B | 171.74B | 150.30B | 140.12B | 144.84B | 139.58B | 112.48B | 122.31B | 131.91B | 130.54B | 120.38B | 0.00 | 0.00 | 0.00 | 0.00 | 225.43B | 108.30B | 93.25B | 78.33B | 69.02B | 59.70B | 55.04B | 49.61B | 46.70B |
| General & Administrative | 374.42B | 358.29B | 366.43B | 281.40B | 256.30B | 228.21B | 183.86B | 179.68B | 192.82B | 194.55B | 152.32B | 139.85B | 0.00 | 0.00 | 0.00 | 0.00 | 372.30B | 351.25B | 307.80B | 269.39B | 250.87B | 228.44B | 202.46B | 154.66B | 127.05B |
| Selling & Marketing | -10.34B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 58.22B | 68.88B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 364.08B | 358.29B | 366.43B | 281.40B | 256.30B | 228.21B | 183.86B | 179.68B | 192.82B | 194.55B | 210.54B | 208.73B | 0.00 | 0.00 | 0.00 | 0.00 | 372.30B | 351.25B | 307.80B | 269.39B | 250.87B | 228.44B | 202.46B | 154.66B | 127.05B |
| Other Expenses | 0.00 | 0.00 | -10.52B | 1.17B | -1.99B | -866.00M | -1.85B | -8.03B | -13.60B | 80.00M | -109.00M | -138.00M | 924.00M | 924.00M | 417.00M | -9.00M | 616.00M | 873.00M | 459.00M | 555.00M | -43.00M | 1.00M | 864.00M | -130.00M | -96.00M |
| Operating Expenses | 532.79B | 526.53B | 527.65B | 432.87B | 394.43B | 372.19B | 321.59B | 284.13B | 301.53B | 326.53B | 341.09B | 329.10B | 378.82B | 488.03B | 556.00B | 537.48B | 597.73B | 459.55B | 401.04B | 347.72B | 319.88B | 288.15B | 257.49B | 204.14B | 173.66B |
| Cost & Expenses | 688.12B | 704.36B | 702.48B | 594.18B | 570.12B | 556.68B | 522.84B | 480.03B | 495.99B | 520.13B | 529.25B | 503.21B | 552.17B | 655.81B | 716.73B | 689.90B | 716.67B | 568.91B | 505.55B | 446.33B | 417.06B | 390.62B | 359.06B | 302.75B | 265.34B |
| Interest Income | 10.80B | 7.24B | 2.40B | 2.15B | 4.02B | 4.86B | 2.56B | 1.85B | 2.02B | 2.43B | 963.00M | 1.12B | 815.00M | 997.00M | 1.25B | 3.17B | 5.33B | 5.12B | 3.35B | 1.70B | 1.34B | 1.47B | 2.78B | 3.19B | 0.00 |
| Interest Expense | 2.39B | 2.27B | 1.69B | 1.36B | 1.46B | 1.56B | 2.97B | 3.24B | 3.49B | 4.89B | 5.55B | 6.69B | 6.89B | 7.42B | 7.66B | 7.63B | 762.00M | 65.00M | 79.00M | 52.00M | 28.00M | 56.00M | 296.00M | 687.00M | 1.13B |
| Depreciation & Amortization | 39.40B | 39.98B | 38.40B | 36.30B | 33.70B | 26.84B | 26.18B | 26.48B | 34.06B | 38.94B | 48.52B | 51.09B | 48.69B | 51.26B | 57.37B | 58.63B | 34.40B | 26.80B | 24.99B | 22.45B | 18.49B | 15.33B | 15.33B | 15.00B | 15.14B |
| EBITDA | 103.11B | 87.26B | 94.55B | 90.05B | 162.94B | 117.75B | 105.81B | 86.93B | 87.99B | 69.56B | 93.36B | 129.21B | 150.23B | 161.25B | 139.31B | 136.75B | 52.81B | 137.20B | 121.15B | 110.06B | 101.90B | 87.85B | 91.74B | 58.53B | 41.81B |
| EBITDA Ratio | 13.90% | 11.72% | 12.50% | 13.97% | 23.46% | 18.33% | 17.66% | 16.21% | 16.06% | 12.71% | 19.86% | 21.84% | 22.48% | 21.31% | 18.02% | 19.04% | 7.35% | 20.37% | 20.80% | 20.93% | 20.37% | 18.05% | 21.25% | 15.70% | 13.82% |
| Operating Income | 53.41B | 40.04B | 53.75B | 51.77B | 125.50B | 86.15B | 77.21B | 59.06B | 51.94B | 28.34B | 71.11B | 70.46B | 95.75B | 113.12B | 86.41B | 91.81B | 17.75B | 105.26B | 95.70B | 86.81B | 83.06B | 75.86B | 72.69B | 58.97B | 37.13B |
| Operating Income Ratio | 7.20% | 5.38% | 7.11% | 8.01% | 18.04% | 13.40% | 12.87% | 10.96% | 9.48% | 5.17% | 11.84% | 12.28% | 14.78% | 14.71% | 10.76% | 11.74% | 2.42% | 15.61% | 15.92% | 16.28% | 16.61% | 16.26% | 16.84% | 16.30% | 12.28% |
| Total Other Income/Expenses | 8.42B | 4.97B | 708.00M | -668.00M | 2.56B | 3.30B | -409.00M | -1.40B | -1.46B | -2.46B | -4.10B | 966.00M | -1.10B | -10.55B | -12.13B | -21.32B | -96.00M | 5.07B | 378.00M | 845.00M | -539.00M | -6.04B | -9.93B | -16.13B | -11.60B |
| Income Before Tax | 61.82B | 45.01B | 54.46B | 52.55B | 128.06B | 89.45B | 76.80B | 57.67B | 50.47B | 25.88B | 58.21B | 71.43B | 94.65B | 102.57B | 74.28B | 70.48B | 17.65B | 110.33B | 96.08B | 87.65B | 82.52B | 69.83B | 62.75B | 42.84B | 25.54B |
| Income Before Tax Ratio | 8.33% | 6.05% | 7.20% | 8.14% | 18.41% | 13.92% | 12.80% | 10.70% | 9.21% | 4.72% | 9.70% | 12.45% | 14.61% | 13.34% | 9.25% | 9.02% | 2.40% | 16.37% | 15.98% | 16.44% | 16.50% | 14.96% | 14.53% | 11.84% | 8.44% |
| Income Tax Expense | 18.04B | -11.82B | 8.74B | 10.07B | 5.60B | 22.97B | 22.38B | 15.42B | -4.57B | -17.58B | 25.03B | 22.88B | 35.71B | 34.79B | 33.41B | 22.13B | 37.19B | 39.20B | 32.23B | 31.80B | 32.93B | -28.61B | 26.10B | 19.63B | -14.20B |
| Net Income | 42.41B | 55.43B | 47.95B | 41.94B | 121.77B | 63.39B | 51.85B | 39.36B | 54.93B | 43.25B | 32.96B | 48.28B | 58.51B | 67.39B | 40.34B | 47.68B | -17.01B | 70.61B | 63.41B | 55.51B | 50.15B | 41.03B | 36.80B | 23.32B | 11.28B |
| Net Income Ratio | 5.72% | 7.45% | 6.34% | 6.49% | 17.50% | 9.86% | 8.64% | 7.30% | 10.03% | 7.89% | 5.49% | 8.42% | 9.03% | 8.76% | 5.02% | 6.10% | -2.32% | 10.47% | 10.55% | 10.41% | 10.03% | 8.79% | 8.52% | 6.45% | 3.73% |
| EPS | 147.86 | 193.31 | 167.27 | 146.95 | 425.01 | 221.02 | 724.71 | 550.52 | 768.92 | 606.28 | 536.52 | 677.52 | 821.32 | 946.08 | 566.32 | 669.40 | -59.32 | 991.40 | 887.24 | 776.88 | 697.04 | 553.36 | 500.64 | 311.51 | 152.13 |
| EPS Diluted | 147.86 | 193.30 | 167.25 | 146.90 | 424.80 | 221.02 | 723.89 | 549.64 | 767.04 | 605.48 | 536.04 | 677.24 | 821.24 | 946.04 | 566.24 | 669.20 | -59.32 | 991.40 | 887.24 | 776.88 | 697.04 | 553.36 | 500.64 | 311.51 | 152.13 |
| Weighted Avg Shares Out | 286.80M | 286.76M | 286.69M | 286.62M | 286.51M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M |
| Weighted Avg Shares Out (Dil) | 286.80M | 286.76M | 286.73M | 286.71M | 286.65M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M |
FDA panel to debate US approval for Alzheimer's drug from Eisai and Biogen
Eisai shares rise as FDA memo raises hopes for full approval of Alzheimer's drug
FDA staff say Eisai's Alzheimer's drug may get full approval despite concerns
Source: https://incomestatements.info
Category: Stock Reports